Ajinomoto Of Japan To Merge Units To Make More Innovative Drugs
This article was originally published in PharmAsia News
Executive SummaryJapan's Ajinomoto plans to merge two of its subsidiaries as of April 1 to coincide with a new program intended to reduce the price of drugs that have lost patent protection
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.